Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.

The Permanente journal - 1 Jan 2017

Louie Vincent, Latt Nyan L, Gharibian Derenik, Sahota Amandeep, Yanny Beshoy T, Mittal Rasham, Bider-Canfield Zoe, Cheetham T Craig

Abstract excerpt

CONTEXT: Traditional hepatitis C virus treatment was limited by low cure rates, side effects, and stringent monitoring requirements. Sofosbuvir, a direct-acting antiviral agent with a cure rate of 96%, was introduced in 2013. However, trials frequently excluded patients with advanced liver disease and prior treatment experience. This study aims to elucidate the real-world cure rates and sofosbuvir safety profile....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to California

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatigue

Share to Interferons

Share to Liver Cirrhosis

Share to Patient Selection

Share to Ribavirin

Share to Sofosbuvir

Source

Open in PubMed Open full text

Identifiers

PMID: 28368787
DOI: 10.7812/TPP/16-096
PMCID: PMC5378486

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.PMID 28368787Read ↗

Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3.Semantic proximity Read ↗

Chronic Hepatitis C Treatment with Direct-Acting Antiviral Agents in a Real-Life Setting.Semantic proximity Read ↗

Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.Semantic proximity Read ↗

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.Semantic proximity Read ↗

Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey.Semantic proximity Read ↗

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Semantic proximity Read ↗

Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.Semantic proximity Read ↗

Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?Semantic proximity Read ↗

Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.Semantic proximity Read ↗

Treatment of hepatitis C: a systematic review.Semantic proximity Read ↗

Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Semantic proximity Read ↗

Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.